NasdaqGS:KRYSBiotechs
Krystal Biotech (KRYS) Revenue Growth Puts VYJUVEK Pipeline Progress In Focus
Krystal Biotech (NasdaqGS:KRYS) reports strong revenue growth alongside progress in its rare disease pipeline.
The company highlights ongoing clinical development for genetic therapies, including VYJUVEK for dystrophic epidermolysis bullosa.
Recent updates focus on broader pipeline advancement in rare genetic conditions with high unmet medical need.
Krystal Biotech enters the spotlight as investors track fresh updates on its revenue trajectory and expanding genetic therapy pipeline. The...